Gland Pharma Shares Recover volatile USFDA Inspection

shares came under pressure on September 2, 2026, falling as much as 2.5% during the session, before recovering the entire decline and trading largely flat in afternoon trade. At around 3:18 PM IST, the stock was quoted at ₹2,873.90, down marginally. The recovery followed a positive regulatory update. The US Food and Drug Administration (USFDA) conducted a routine Good Manufacturing Practice (GMP) inspection at Gland Pharma’s VSEZ Sterile Oncology formulations facility and API facility in Visakhapatnam from August 24 to September 1, 2026. The inspection concluded with **zero Form 483 observations**, a reassuring outcome for the company and investors. Gland Pharma specialises in complex injectable products across sterile injectables, oncology and ophthalmics. Its portfolio includes NCE-1s, First-to-File products and 505(b)(2) filings, while the company is expanding into peptides, long-acting injectables, suspensions and innovative drug-delivery systems. The stock has a 52-week range of ₹1,574–₹3,040 and a market capitalisation of about ₹47,318 crore. Disclaimer: Investments in securities are subject to market risk. This is for informational purposes only. Investors must verify information before investing and consider their financial position & risk profile."